ARTICLE | Clinical News
TTI-621: Preliminary Ph Ia data
December 15, 2016 11:17 PM UTC
Preliminary data from 18 patients with relapsed or refractory lymphomas in the dose-escalation Phase Ia portion of an open-label, North American Phase Ia/Ib trial showed that once-weekly IV TTI-621 le...
BCIQ Company Profiles
BCIQ Target Profiles